Since about 20% of MM patients demonstrate a t(11;14) (that activates BCL-2) and an overexpression of BCL-2, a possible anti-myeloma activity of venetoclax in MM has been investigated. This evidence concerns the gene BCL2 and plasma cell myeloma.